HOWL - NASDAQ
Werewolf Therapeutics, Inc.
$1.04
-3.7%Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotWerewolf Therapeutics, Inc. Management Team
Mr. Steven H. Bloom R.Ph.
Chief Business Officer
Mr. Timothy W. Trost CPA
Chief Financial Officer, Treasurer & Assistant Secretary
Compensation
$678,675
Dr. Randi Isaacs M.D.
Chief Medical Officer
Compensation
$722,845
Dr. Chulani Karunatilake Ph.D.
Chief Technology Officer
Compensation
$343,431
Dr. Daniel J. Hicklin Ph.D.
Founder, Chief Executive Officer, President, Secretary & Director
Compensation
$985,732
Dr. William Winston Ph.D.
Senior Vice President of Research
Werewolf Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $231K and sold $6.52M worth of HOWL shares, resulting in $6.29M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
891.9K
635.04K
-635K
-$635K
6-9 Months
0
0.00
5.1M
5.89M
-5.9M
-$5.89M
9-12 Months
179.4K
230.83K
0
0.00
+231K
+$231K
Top Buyers
Morrison Briggs
Director
$35K
Lazarus Alon
Director
$35K
Chatterjee Meeta
Director
$35K
Evnin Luke
Director
$35K
Sherman Michael A.
Director
$35K
Top Sellers
Mpm Bioventures 2014, L.P.
Other: Former 10% Owner
$2.22M
Gadicke Ansbert
Other: Former 10% Owner
$2.22M
Evnin Luke
Director
$2.08M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.29M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
SEC Filings
HOWL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 12, 2024 | May 24, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 21, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 01, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.